SYNLOGIC INC. news, videos and press releases
For more news please use our advanced search feature.
SYNLOGIC INC. - More news...
SYNLOGIC INC. - More news...
- Synlogic Reports Third Quarter 2024 Financial Results
- Synlogic Reports Second Quarter 2024 Financial Results
- Synlogic Reports First Quarter 2024 Financial Results
- Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
- Synlogic Adopts Limited Duration Stockholders Rights Plan
- Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
- Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
- Synlogic Provides Corporate Update and Outlook for 2024
- Synlogic Announces Contract with the Air Force Research Lab
- Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
- Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
- Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
- Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
- Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
- Synlogic Announces Reverse Stock Split
- Synlogic to Participate in Chardan’s Genetic Medicines Conference
- Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
- Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
- Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
- Synlogic Announces International Nonproprietary Name Selection for SYNB1934
- Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
- Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
- Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
- Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
- Synlogic to Present at the Jefferies Global Healthcare Conference
- Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
- Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
- Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
- Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
